Clinical Study to Evaluate the Efficacy and Safety of Matrix Pro Treatment

NCT ID: NCT06726122

Last Updated: 2025-06-15

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-28
• Study Completion Date: 2028-05-31

Brief Summary

This is a non-randomized, multi-center, open-label, prospective clinical trial evaluating clinical treatments with the Matrix Pro Applicator for the improvement of facial and/or submental and neck laxity.

Detailed Description

Eligible participants will receive up to three treatments with the Matrix Pro Applicator of the Profound Matrix System to address facial and neck laxity. Treatments will be approximately 6 weeks apart (± 2 weeks). All participants will undergo follow-up evaluations at 1 month (4 weeks ± 2 weeks) and 3 months (13 weeks ± 2 weeks) after the final treatment. Additional follow-up visits may be required per Sponsor and PI discretion

Conditions

Skin Laxity; Wrinkle; Skin Condition

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Matrix Pro Treatment Group

Study subjects receive up to three (3) study treatments with the Matrix Pro applicator

Group Type: EXPERIMENTAL

Profound Matrix

Intervention Type: DEVICE

Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).

Interventions

Profound Matrix

Treatment visits are limited to up to three (3) study treatments (with treatment intervals 6 weeks ± 2 weeks).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Healthy female and male subjects between 18 to 84 years of age with Fitzpatrick Skin Type I - VI.

2. Willing to receive Profound Matrix treatments with Matrix Pro applicator

3. Able and willing to comply with the treatment/follow-up schedule and comply with all study (protocol) requirements.

4. Willing to provide signed, informed consent to participate in the study

5. Willing to have photographs and images taken of the treated areas to be used in evaluations, publications, presentations, and marketing materials (Subject identity will be masked).

Exclusion Criteria

Any of the following will exclude the subject from the study:

1. Pregnant or planning to become pregnant, having given birth less than 3 months prior to enrollment into the study, and/or breast feeding

2. Pacemaker or internal defibrillator or any active electrical implant anywhere in the body

3. Superficial metal or other implants in the treatment area, except superficial dental implants, unless the implants can be removed or covered with rolled gauze during treatment

4. Skin cancer in the treatment area or history of melanoma

5. History of current cancer and/or subject has undergone chemotherapy within the last 12 months

6. Severe concurrent conditions, such as cardiac disorders

7. Impaired immune system or use of immunosuppressive medications, except for topical products and inhaler medications per investigator discretion

8. Herpes Simplex Virus (HSV) in the intended treatment area unless treated following a prophylactic regimen

9. Poorly controlled endocrine disorders such as poorly controlled diabetes

10. Active skin condition in the treatment area such as skin infection, sores, psoriasis, eczema, rash, or open wounds

11. History of abnormal wound healing, keloid, or hypertrophic scar formation, as well as very thin or fragile skin

12. History of collagen vascular disease or vasculitic disorders

13. Known allergy to medication to be used during treatments such as allergy to topical anesthetic (e.g., lidocaine)

14. History of systemic corticosteroid therapy in past six months

15. Tattoos or permanent makeup in the intended treatment area

16. Excessively tanned skin

17. Facelift in the last 12 months

18. Aesthetics treatments/procedures (e.g., facial resurfacing and deep chemical peeling) within the last 4 months within the intended treatment area

19. Neuromodulator injections (e.g., Botox®), collagen, non-permanent dermal filler, fat injections or other methods of augmentation with injected biomaterial in the intended treatment area within the last 3 months

20. Permanent synthetic fillers (e.g., silicone) in the intended treatment area

21. Absorbable facial threads within the last 12 months or non-absorbable facial threads within the intended treatment area

22. In the opinion of the Investigator, the subject is unwilling or unable to adhere to the study requirements or is otherwise unsuitable for study participation

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 84 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Candela Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Konika Schallen, MD

Role: STUDY_DIRECTOR

Candela Corporation

Locations

Kliniek voor Esthetische Geneeskunde

Amsterdam, EK, Netherlands

Illuminate Skin & Wellness Clinic

Kings Hill, Kent, United Kingdom

GHB Clinic

London, , United Kingdom

Countries

Netherlands; United Kingdom

Other Identifiers

PFX22003_EU

Identifier Type: -

Identifier Source: org_study_id